|
1
|
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.
|
Am J Kidney Dis
|
2008
|
15.04
|
|
2
|
Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
|
Kidney Int
|
2005
|
10.42
|
|
3
|
Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function.
|
J Am Soc Nephrol
|
2005
|
5.99
|
|
4
|
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
|
N Engl J Med
|
2010
|
5.48
|
|
5
|
A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.
|
N Engl J Med
|
2009
|
3.37
|
|
6
|
Timing of onset of CKD-related metabolic complications.
|
J Am Soc Nephrol
|
2008
|
2.60
|
|
7
|
Fanconi syndrome and renal failure induced by tenofovir: a first case report.
|
Am J Kidney Dis
|
2002
|
2.41
|
|
8
|
Epoetin-associated pure red cell aplasia: past, present, and future considerations.
|
Transfusion
|
2008
|
1.73
|
|
9
|
Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts.
|
J Biol Chem
|
2007
|
1.72
|
|
10
|
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
|
Am J Kidney Dis
|
2012
|
1.38
|
|
11
|
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.
|
Kidney Int
|
2005
|
1.31
|
|
12
|
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
|
Blood
|
2005
|
1.30
|
|
13
|
Pure red cell aplasia induced by erythropoiesis-stimulating agents.
|
Clin J Am Soc Nephrol
|
2008
|
1.11
|
|
14
|
Erythropoietin receptors: their role beyond erythropoiesis.
|
Nephrol Dial Transplant
|
2005
|
0.97
|
|
15
|
Importance of biologic follow-ons: experience with EPO.
|
Best Pract Res Clin Haematol
|
2005
|
0.93
|
|
16
|
Sensitization from transfusion in patients awaiting primary kidney transplant.
|
Nephrol Dial Transplant
|
2013
|
0.90
|
|
17
|
Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
|
Nephrol Dial Transplant
|
2004
|
0.89
|
|
18
|
Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation.
|
Transplantation
|
2014
|
0.83
|
|
19
|
The new Mayo Clinic equation for estimating glomerular filtration rate.
|
Ann Intern Med
|
2005
|
0.82
|
|
20
|
Transcriptional control of epithelial differentiation during kidney development.
|
J Am Soc Nephrol
|
2003
|
0.82
|
|
21
|
Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression?
|
Nephrol Dial Transplant
|
2002
|
0.78
|
|
22
|
Renewal of FSP1: a marker of fibrogenesis on human renal biopsies.
|
Kidney Int
|
2005
|
0.75
|
|
23
|
Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.
|
Am J Kidney Dis
|
2006
|
0.75
|